Investor Update
Basel, 16 October 2006
Seven abstracts on innovative anaemia drug MIRCERA accepted for presentation at the American Society of Nephrology Annual Meeting
New study results will be unveiled from Roche’s robust Phase III clinical development program for its investigational anti-anaemia drug, MIRCERA at the upcoming 39th Annual Meeting of the American Society of Nephrology in San Diego taking place November 14-19.
Among the highlights will be the first public presentation of MIRCERA results from the two anaemia ‘correction’ studies (AMICUS and ARCTOS) to treat anaemia in patients with chronic kidney disease on dialysis and not on dialysis, as well as further analyses of haemoglobin stability and special populations from the ‘maintenance’ studies.
In addition, there will be two presentations of new results from the GAIN study which look at the effect of switching to subcutaneous NeoRecormon (epoetin beta) on the management of anaemia in patients on dialysis, one presentation from the IRIDIEM study, reporting on the use of evidence based guidelines for the management of CKD in patients with diabetes, and a presentation of new data from the French NeoRecormon DiaNE study.
Programme
The ASN abstracts selected for presentation, as well as the meeting schedule can be viewed on-line at www.asn-online.org.
Seven abstracts on innovative anaemia drug MIRCERA accepted for presentation at the American Society of Nephrology Annual Meeting
New study results will be unveiled from Roche’s robust Phase III clinical development program for its investigational anti-anaemia drug, MIRCERA at the upcoming 39th Annual Meeting of the American Society of Nephrology in San Diego taking place November 14-19.
Among the highlights will be the first public presentation of MIRCERA results from the two anaemia ‘correction’ studies (AMICUS and ARCTOS) to treat anaemia in patients with chronic kidney disease on dialysis and not on dialysis, as well as further analyses of haemoglobin stability and special populations from the ‘maintenance’ studies.
In addition, there will be two presentations of new results from the GAIN study which look at the effect of switching to subcutaneous NeoRecormon (epoetin beta) on the management of anaemia in patients on dialysis, one presentation from the IRIDIEM study, reporting on the use of evidence based guidelines for the management of CKD in patients with diabetes, and a presentation of new data from the French NeoRecormon DiaNE study.
Programme
The ASN abstracts selected for presentation, as well as the meeting schedule can be viewed on-line at www.asn-online.org.
All
trademarks used or mentioned in this release are legally protected.